A Phase II Exploratory Study of Iparomlimab and Tuvonralimab Combined With Chemotherapy in Neoadjuvant Treatment of HR+/HER2- Breast Cancer Patients

The dosage of Iparomlimab and Tuvonralimab Injection is 5mg/kg, administered intravenously, with each treatment cycle lasting every 3 weeks. The chemotherapy regimen is AC-T: epirubicin 100mg/m2, cyclophosphamide 600mg/m2, every 3 weeks for 4 cycles; followed by paclitaxel 80mg/m2, every week for 12 cycles. A total of 8 cycles of neoadjuvant chemotherapy combined with immunotherapy were performed before the surgery. It is recommended that the surgery be conducted within 4 weeks after the completion of neoadjuvant treatment. The postoperative adjuvant treatment can be continued with postoperative adjuvant chemotherapy and the treatment of the etolo combination antibody according to the decision of the researcher and/or the willingness of the subject.